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This study aims to identify key miRNAs in circulation, which predict ongoing beta-cell destruction and regeneration in children
with newly diagnosed Type 1 Diabetes (T1D). We compared expression level of sera miRNAs from new onset T1D children and
age-matched healthy controls and related the miRNAs expression levels to beta-cell function and glycaemic control. Global miRNA
sequencing analyses were performed on sera pools from two T1D cohorts (n = 275 and 129, resp.) and one control group (n =
151). We identified twelve upregulated human miRNAs in T1D patients (miR-152, miR-30a-5p, miR-181a, miR-24, miR-148a,
miR-210, miR-27a, miR-29a, miR-26a, miR-27b, miR-25, miR-200a); several of these miRNAs were linked to apoptosis and beta-
cell networks. Furthermore, we identified miR-25 as negatively associated with residual beta-cell function (est.:−0.12, P = 0.0037),
and positively associated with glycaemic control (HbA1c) (est.: 0.11, P = 0.0035) 3 months after onset. In conclusion this study
demonstrates that miR-25 might be a “tissue-specific” miRNA for glycaemic control 3 months after diagnosis in new onset T1D
children and therefore supports the role of circulating miRNAs as predictive biomarkers for tissue physiopathology and potential
intervention targets.
1. Introduction
As an autoimmune disease-type 1 diabetes (T1D) results
from an immune-mediated destruction of the insulin pro-
ducing beta-cells reflected by the appearance of the pancre-
atic autoantibodies. The destruction of these cells implies
a progressive, irreversible loss of the endogenous insulin
production, leading to daily treatment with exogenous
insulin.
At time of diagnosis a child with T1D is estimated to
have lost approx. 80–90% of the insulin producing beta-
cell function/mass. Shortly after the initial insulin treat-
ment, several children experience a period of increased
endogenous insulin production followed by a reduced need
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of exogenous insulin, referred to as the remission phase
[1]. The regenerative potential that exists within this time
interval particularly in children gives a unique possibility of
intervention treatment, that is, with beta-cell growth factors
to maintain the individual insulin production, leading to
improved glycaemic control and fewer complications in eyes,
kidneys, and nerves.
The hypothesis of the study is that potential new
biomarkers (miRNAs and/or miRNA patterns) in serum
from children with newly diagnosed T1D can predict
destruction or regeneration of the endogenous residual beta-
cell function. miRNAs are small noncoding RNAs involved
in posttranscriptional regulation of protein translation either
through mRNA destabilization or inhibition [2, 3]. miRNAs
are found in solid tissues and cell culture samples, and
several studies confirm their presences in body fluids as
blood, saliva, urine, and serum [4–7]. The stability of serum
miRNAs has been investigated under harsh conditions
including boiling, low/high pH, extended storage, and freeze-
thaw cycles without any significant diﬀerence compared to
nontreated serum samples [8]. Taken together these results
show that serummiRNAs, are stable and that theymay reflect
cellular dysfunctions in various chronic diseases. In addition,
several miRNAs clearly have a role in metabolic pathways
for example, miR-33a/b inhibition in nonhuman primates
raises plasma HDL cholesterol and lowers triglycerides [9],
and silencing of miR103/107 seems to have beneficial eﬀects
on insulin sensitivity in obesemice possibly through its target
gene caveolin-1 which is a critical regulator of the insulin
receptor [10].
The objective of the current study was therefore to
identify new biomarkers (key miRNAs/miRNA patterns),
which are predictive for destruction or regeneration of
the endogenous residual beta-cell function by investigating
miRNAs in serum samples from new-onset T1D patients and
age-matched controls.
2. Methods
2.1. Study Cohorts. Serum samples from two unique T1D
cohorts and one control group were analysed for miRNA
expression.
2.2. International Remission Phase Cohort (The Hvidoere
Cohort). The Hvidoere Remission Phase cohort is a lon-
gitudinally, observational cohort of newly diagnosed T1D
children collected through 18 paediatric centres primarily
in Europe [11]. Blood samples for centrally determined
HbA1c, stimulated C-peptide, glucagon, incretin hormones,
cytokines, immunology, and DNA were collected prospec-
tively at a meal-stimulated test 1, 6, and 12 months after
diabetes onset. 275 patients were included in the study.
2.3. The Danish Remission Cohort. The Danish Remission
Phase cohort includes new onset T1D children treated at
four Danish paediatric centres. The study design is analogous
to the Hvidoere cohort, except for the inclusion of a three-
month meal-stimulated test. 129 children were included in
the study [12].
2.4. Healthy Control Children (The Copenhagen Puberty
Study). Healthy controls consist of girls and boys between
6.7 and 13.7 years, recruited from public schools in the
Copenhagen area as part of a mixed cross-sectional and
longitudinal study, the COPENHAGEN Puberty Study [13,
14]. Information on gender, age, pubertal stage, height,
and weight was recorded. Blood samples were analysed
for metabolic parameters (glucose, insulin, cholesterol, and
triglycerides). 151 children were included in the present
study.
2.5. miRNA Purification, Solexa Sequencing, and Quantitative
RT-PCR. The work flow was separated into three steps:
(i) initial screening by high-throughput Solexa sequencing
using pooled serum samples, (ii) qRT-PCR validation in a
large number of individual serum samples arranged in mul-
tiple training and testing sets, and (iii) statistical evaluation
of the diagnostic or prognostic value of the serum miRNA
profiling system.
2.5.1. Serum Pools and miRNA Purification. Serum pools
were prepared from all three cohorts. From the Hvidoere
cohort 100 μL serum from 275 children was pooled, from the
Danish cohort 200 μL serum from 129 children was pooled,
and finally 200 μL serum from 151 healthy control children
was pooled. Total RNAwas extracted from serum pools using
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. Furthermore, total RNA
from all individuals in the three cohorts (the Hvidoere, the
Danish, and healthy controls) was isolated and stored at
−80◦C for later testing of candidate miRNAs.
2.5.2. Solexa Sequencing. The pooled samples from the 3
cohorts (a total of 5–10 μg RNA) were sequenced on the
Solexa sequencing platform (Illumina). After PAGE purifica-
tion of small RNA molecules under 30 bases and ligation of a
pair of Solexa adaptors to their 5′ and 3′ ends, the small RNA
molecules were amplified using the adaptor primers for 17
cycles, and fragments around 90 bp (small RNA+adaptors)
were isolated from agarose gel. The purified DNA was
used directly for cluster generation and sequencing analysis
using the Illumina Genome Analyzer IIx according to the
manufacturer’s instructions. Image files were generated by
the sequencer and were processed to produce digital-quality
data. After masking the adaptor sequences and the removal
of contaminated reads, clean reads were processed for in
silico analysis as previously described [8]. After comparing
the serum miRNA profile in the control group versus the
patients, a panel of diﬀerentially (as defined by copy number
>100 and 2-fold altered expression) expressed miRNAs was
derived.
2.5.3. Quantitative RT-PCR of Mature miRNA. Quantifi-
cation of mature miRNAs was carried out using Taqman
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miRNA probes (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions. Briefly, 2 μL
of total RNA is reverse-transcribed to cDNA using AMV
reverse transcriptase and a stem-loop RT primer (Applied
Biosystems). Real-time PCR was performed using a TaqMan
PCR kit on an Applied Biosystems 7300 Sequence Detec-
tion System (Applied Biosystems). All reactions, including
non-template controls, were run in triplicate. Twenty-four
candidate miRNAs were reanalysed by qRT-PCR analyses on
individual samples. We examined the expression levels of the
candidate miRNAs in a subset of the cohorts consisting of
108 patients (1-month samples from the Danish Remission
Phase cohort and 12-month samples from the Hvidoere
cohort) and 54 controls.
2.6. Statistics. For the cohort comparisons each miRNA was
studied separately as function of cohort, age, and sex on a
logarithmic scale. All comparisons were adjusted formultiple
testing by Hochberg approach.
Statistical evaluation of miRNA association to disease
progression (endpoints: stimulated C-peptide and HbA1c)
was done by multiple linear regression analysis adjusting
for age and sex. miRNA expression was presented as 2(−ΔCt)
transformed values (the diﬀerence in Ct value between a
given miRNA and the reference miRNA (a combination
of three miRNAs of the let-7 family); all values represent
the geometricmean of triplicates measures). Stimulated C-
peptide was studied on logarithmic scale to obtain normal
distribution, while HbA1c was normally distributed. The
results were interpreted as the change in actual HbA1c values
(%) and the percentage change in stimulated C-peptide
corresponding to the range between the 25 percentile and the
75 percentile (interquartile range) of the ΔCt values of the
relevant miRNA. Data were analysed using SAS (version 9.2,
SAS Institute; Cary, NC). A P-value of <0.05 was considered
statistically significant.
2.7. Ethical Approval. Ethical approval has been obtained
for the Hvidoere and the Danish Remission Phase Studies
allowing the samples to be analyzed for miRNAs (KA 99063
and KA 04010gm, resp.). The COPENHAGENPuberty Study
(ClinicalTrialsGov ID NCT01411527) including additional
genetic and epigenetic studies was approved by the ethical
committee (KF 01 282212 and V200.1996/90).
3. Results
3.1. Comparing Serum miRNAs Expression Levels between
Two Paediatric Type 1 Diabetes Cohorts and an Age-Matched
Control Group. miRNA was purified from a pool of serum
from each cohort (serum samples were taken 1 month
after diagnosis for both diabetes cohorts), and the presence
and levels of miRNAs were identified by global Solexa
sequencing. We identified in total 240 diﬀerent miRNAs
from these cohorts; this corresponds to approx. 15% of all
known human miRNAs (miRbase18 identifies 1527 human
miRNAs). 47 miRNAs fulfilled our criteria for diﬀerential
expression between the diabetes cohorts and the control
group (>100 copy number and 2-fold altered expression).
Of these 24 miRNAs (miR-103, miR-10a, miR-125b, miR-
134, miR-199a, miR-200c, miR-21, miR-26b, miR-29b, miR-
340, miR-320a, miR-222, miR-152, miR-30a-5p, miR-181a,
miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a,
miR-27b, miR-25, and miR-200a) were selected for further
analyses by qRT-PCR in a subset (n = 54) of samples
from each cohort. Consistently we found all 24 miRNAs
upregulated by both Solexa sequencing and qPCR analyses.
A combination of three miRNAs of the let-7 family was used
as reference for normalisation of miRNA expression levels
measured by qRT-PCR. By regression analysis adjusting for
age, sex, and multiple testing we found 12 miRNAs (miR-
152, miR-30a-5p, miR-181a, miR-24, miR-148a, miR-210,
miR-27a, miR-29a, miR-26a, miR-27b, miR-25, and miR-
200a) to be significantly diﬀerentially expressed between
either both diabetes cohorts and the control group or just
one of the diabetes cohorts and the controls (Table 1) (P <
0.05). The ΔCt values of these 12 miRNAs are presented in
Figure 1.
3.2. Association between Qualified miRNAs and Disease
Progression in Children with New Onset Type 1 Diabetes.
The qualified miRNAs with diﬀerential expression pattern
between cases and controls were analysed by qRT-PCR
analyses for association with disease progression in the
two diabetes cohorts. Disease progression was described by
glycaemic control as assessed by HbA1c or residual beta-
cell function estimated by stimulated C-peptide. In the
Danish cohort miR-25 measured at 1 month after disease
onset was negatively associated with the HbA1c level and
positively associated with stimulated C-peptide levels 3
months after onset. The regression analyses suggest a 0.22%
decrease in HbA1c level (0.08–0.37) (P = 0.0035) and a
22.4% (8.3–34.3) (P = 0.0037) increase in stimulated C-
peptide between the 25–75 interquartile range of ΔmiR-25
(Figures 2(a) and 2(b)). miR-25 measured at 12 months
after disease onset was not associated with stimulated C-
peptide or HbA1c in the Hvidoere cohort (data not shown).
Furthermore, we analysed for association between the 12
qualified miRNAs and the pancreatic autoantibodies (GAD,
IA, IA-2A and ZnT8Ab) (data not shown). We found no
association between these parameters in any of the cohorts.
4. Discussion
This is the first study to compare miRNA levels in serum
samples from children with or without T1D. Serum samples
from approximately 400 new onset T1D children and
150 healthy age-matched controls were analysed. Twelve
diﬀerentially expressed miRNAs between cases and controls
were identified. Several of these miRNAs are involved in
regulation of apoptosis (miR-181a, miR-24, miR-25, miR-
210, andmiR-26a) [15–19] and beta-cell regulatory networks
(miR-24, miR-148a, miR-200a, and miR-29a) [20]. Even
more importantly we found quite a few miRNAs with yet
unidentified function related to T1D as miR-152 and miR-
30a-5p.
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Figure 1: Twelve miRNAs were diﬀerentially expressed between the diabetes cohorts and the controls. ΔCt values are plotted for each cohort
(Hvidoere (red), Danish (green) and controls (blue)). The bars represent geometric means of the ΔCt values ± SD.
miRNAs are known to play a central role in posttran-
scriptional gene regulation and are involved in many cellular
processes, such as diﬀerentiation, proliferation, and apopto-
sis [20]. miRNAs are detectable in cell-free circulation, that
is, plasma and serum, and thus have been investigated as
noninvasive biomarkers in several diseases and pathologic
processes. In type 2 diabetes (T2D), which is characterized
by chronic elevations of blood glucose levels and insulin
resistance, one study identified a unique plasma miRNA
signature for T2D, which included reduced levels of miR-
15a, miR-20b, miR-21, miR-24, miR-126, miR-191, miR-197,
miR-223, miR-320, miR-486 and elevated levels of miR-28-
3p. Intriguingly, a reduction in the level of some of these
miRNAs (miR-126, miR-15a, and miR-223) was already
detectable years before the manifestation of diabetes [21].
Of these, only miR-24 overlaps with our observation. miR-
24 is a regulator of apoptosis [16] and TGFβ signaling [22]
suggesting a role in inflammation which is important in both
T1D and T2D development [23]. A study by Kong et al. [24]
analyzed seven diabetes-related miRNA candidates in serum
from newlydiagnosed T2D patients, prediabetic and healthy
subjects and found miR-34a to be the strongest predictor of
T2D. No overlap with the markers identified by Zampetaki
et al. [21] was observed.
Current circulating biomarkers for T1D and residual
beta-cell function are based on specific immunoglobulin
(autoantibodies) and C-peptide measurements which are
expensive and time consuming in a routine clinical setting.
The development of new protein-based biomarkers is often
rather cumbersome because of the complexity of protein
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Table 1: List of miRNAs diﬀerentially expressed in sera from children and adolescents with newly diagnosed T1D compared to sera from
age-matched controls.
Systematic miRNA name ΔCt change Pcorrected value Regulation T1D/Controls
Diﬀerence in
following cohorts
hsa-miR-152 2.09 <0.0001 Up Hvidoere/controls
hsa-miR-30a-5p 1.52 <0.0001 Up Hvidoere/controls
Danish/controls
hsa-miR-181a 2.30 <0.0001 Up Hvidoere/controls
Danish/controls
hsa-miR-24 2.25 <0.0001 Up Hvidoere/controls
hsa-miR-148a 2.25 0.00015 Up Hvidoere/controls
hsa-miR-210 1.65 0.00078 Up Hvidoere/controls
hsa-miR-27a 2.79 0.00139 Up Hvidoere/controls
hsa-miR-29a 2.39 0.00636 Up Hvidoere/controls
hsa-miR-27b 1.13 0.00953 Up Hvidoere/controls
hsa-miR-26a 1.31 0.01554 Up Hvidoere/controls
Danish/controls
hsa-miR-25 1.53 0.02013 Up Hvidoere/controls
Danish/controls
hsa-miR-200a 1.23 0.02957 Up Hvidoere/controls
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Figure 2: (a) A significant negative association between miR-25 one month after diagnosis and HbA1c (%) was shown at 3 months in the
Danish Remission Phase Cohort (P = 0.003) while (b) stimulated C-peptide (pmol/L) was positively associated to miR-25 at the same time
point (P = 0.0045).
composition in blood, the diversity of posttranslational
modifications, the low abundance of many proteins, and
challenges in developing high-sensitivity assays.
The precise cellular release mechanisms of miRNA are
largely unknown, and, therefore, the role of circulating miR-
NAs is not fully understood. However, miRNAs oﬀer many
features as attractive biomarkers: stability and evolutionary
conservation, and because they can be detected by real-time
PCR, assays can be highly sensitive and specific.
Interestingly we found an association between miR-25
and better glycaemic control and residual beta-cell function.
There have been several studies linking the miR-25 to
diﬀerent pathological conditions especially in cancer. Several
reports associate high serummiR-25 with breast cancer, non-
small-cell lung carcinoma and hepatocellular carcinoma [8,
25–27]. Furthermore, miR-25 has been found to be expressed
in several malignant cell lines (ovarian cancer cell line and
cholangiocarcinoma), where it is involved in regulation of
apoptosis and cell proliferation by targeting proapoptotic
proteins as Bim and Trail (TNF-related apoptosis inducing
ligand) [17, 28]. A previous study in an experimental diabetic
nephropathy model investigated the role of miRNAs in the
regulation of NADPH expression during hyperglycaemia and
found miR-25 was significantly reduced in kidney from these
animals [18]. Our present findings of improved residual
beta-cell function in patients with high level of miR-25 are
in accordance with these results, suggesting a role of miR-25
on cell proliferation of the endocrine cells of the pancreas.
This is also supported by the lack of association between
miR-25 and the degree of autoimmunity (as assessed by
presence of autoantibodies) in our study. The concordance
between improved stimulated C-peptide and better HbA1c
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levels supports the potential role of this miRNA during
disease progression in these children, and that is despite the
limited number of individuals included in this study.
This study provides suggestive evidence for the role
of miRNAs as clinical applicable biomarkers in T1D. The
association of miR-25 with improved glycaemic control
and better residual beta-cell function may indicate that
this miRNA could be an important biomarker that could
be used during early and intensive management of newly
diagnosed diabetes to improve blood glucose control and
reduce microvascular complications. These findings should
be confirmed in an independent study population; however,
we are currently investigating the miR-25 levels in all
patients from our study cohorts at diﬀerent time points
during disease progression. This study can serve as model
for conceptualising the use of miRNAs as clinical relevant
biomarkers in which they potentially will be used as bene-
ficial predictors to evaluate clinically meaningful changes in
intervention therapies designed to preserve/regenerate beta-
cell function in new onset T1D.
5. Conclusions
This study shows that 12 miRNAs have increased expression
levels in children with new onset T1D compared to age-
matched healthy controls. Furthermore, the residual beta-
cell function and glycaemic control after 3 months of clinical
disease associate with miR-25 expression level present soon
after diagnosis. These findings indicate a potential role for
miRNAs in the understanding of disease mechanisms at
an early time point; this knowledge may in the future be
translated into optimized and individualized diabetes man-
agement (bench-to-bedside) to the benefit of the patients.
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